Dr Ebens during that time Dr Ebens as head of Research at Vera Therapeutics, a San Francisco, California based, clinical stage biotechnology company. Dr Ebens is a drug developer, having overseen the advancement of a dozen drug development projects from concept to clinical development including polatuzumab and mosunetuzumab which are FDA approved and marketed for use in B-cell malignacies. At Juno, Dr Ebens was instrumental in establishing the scientific capabilities of the company in the emerging field of CAR-T. Previously, Dr Ebens held senior executive positions at global pharma and biotechnology leaders Genentech and Exelixis, where he worked from concept to clinic across multiple therapeutic platforms including targeted small-molecule therapies, antibodies, antibody-drug conjugates, and T cell recruiting antibodies. He has also held roles in biotech companies including Bioseek and NGM Biopharmaceuticals. He is a Member of the Risk Committee.
